Zoë Thomas1,2, Marta Novak3,4, Susanna Gabriela Torres Platas1,2, Maryse Gautier1, Angela Potes Holgin1,2, Rebecca Fox1,2, Marilyn Segal1,2, Karl J Looper1,2, Mark Lipman5, Steven Selchen6, Istvan Mucsi4,7, Nathan Herrmann6, Soham Rej8,2,6. 1. McGill Meditation and Mind-Body Medicine Research Clinic and Geri-PARTy Research Group and. 2. Department of Psychiatry, McGill University, Montreal, Quebec, Canada. 3. Centre for Mental Health, University Health Network, and Department of Psychiatry. 4. Institute of Behavioral Sciences, Semmelweis University, Budapest, Hungary. 5. Department of Nephrology, Jewish General Hospital, Montreal, Quebec, Canada. 6. Department of Psychiatry, Sunnybrook Health Sciences Centre, and. 7. Multiorgan Transplant Program and Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada; and. 8. McGill Meditation and Mind-Body Medicine Research Clinic and Geri-PARTy Research Group and soham.rej@mail.mcgill.ca.
Abstract
BACKGROUND AND OBJECTIVES: Up to 50% of patients undergoing hemodialysis suffer from symptoms of depression and/or anxiety. Access to traditional pharmacotherapies and psychotherapies for depression or anxiety in this patient population has been inadequate. The objective of this study was to investigate the feasibility and effectiveness of brief mindfulness meditation intervention for patients on hemodialysis with depression and anxiety symptoms. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study was a randomized, controlled, assessor-blinded trial conducted in an urban hemodialysis unit. Forty-one patients were randomly assigned to intervention (n=21) and treatment-as-usual (n=20) groups. The intervention group received an 8-week individual chairside meditation intervention lasting 10-15 minutes, three times a week during hemodialysis. Feasibility outcomes were primarily assessed: enrollment rates, intervention completion rates, and intervention tolerability. Symptoms of depression and anxiety were measured using the Patient Health Questionnaire (PHQ-9) and the General Anxiety Disorder-7 (GAD-7). RESULTS: Of those deemed eligible for the study, 67% enrolled (41 of 61). Of the participants randomized to the intervention group, 71% completed the study, with meditation being well tolerated (median rating of 8 of 10 in a Likert scale; interquartile range=10-5 of 10). Barriers to intervention delivery included frequent hemodialysis shift changes, interruptions by staff or alarms, space constraints, fluctuating participant medical status, and participant fatigue. Meditation was associated with subjective benefits but no statistically significant effect on depression scores (change in PHQ-9, -3.0±3.9 in the intervention group versus -2.0±4.7 in controls; P=0.45) or anxiety scores (change in GAD-7, -0.9±4.6 versus -0.8±4.8; P=0.91). CONCLUSIONS: On the basis of the results of this study, mindfulness meditation appears to be feasible and well tolerated in patients on hemodialysis with anxiety and depression symptoms. The study did not reveal significant effects of the interventions on depression and anxiety scores. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_10_12_CJASNPodcast_17_12_.mp3.
RCT Entities:
BACKGROUND AND OBJECTIVES: Up to 50% of patients undergoing hemodialysis suffer from symptoms of depression and/or anxiety. Access to traditional pharmacotherapies and psychotherapies for depression or anxiety in this patient population has been inadequate. The objective of this study was to investigate the feasibility and effectiveness of brief mindfulness meditation intervention for patients on hemodialysis with depression and anxiety symptoms. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study was a randomized, controlled, assessor-blinded trial conducted in an urban hemodialysis unit. Forty-one patients were randomly assigned to intervention (n=21) and treatment-as-usual (n=20) groups. The intervention group received an 8-week individual chairside meditation intervention lasting 10-15 minutes, three times a week during hemodialysis. Feasibility outcomes were primarily assessed: enrollment rates, intervention completion rates, and intervention tolerability. Symptoms of depression and anxiety were measured using the Patient Health Questionnaire (PHQ-9) and the General Anxiety Disorder-7 (GAD-7). RESULTS: Of those deemed eligible for the study, 67% enrolled (41 of 61). Of the participants randomized to the intervention group, 71% completed the study, with meditation being well tolerated (median rating of 8 of 10 in a Likert scale; interquartile range=10-5 of 10). Barriers to intervention delivery included frequent hemodialysis shift changes, interruptions by staff or alarms, space constraints, fluctuating participant medical status, and participantfatigue. Meditation was associated with subjective benefits but no statistically significant effect on depression scores (change in PHQ-9, -3.0±3.9 in the intervention group versus -2.0±4.7 in controls; P=0.45) or anxiety scores (change in GAD-7, -0.9±4.6 versus -0.8±4.8; P=0.91). CONCLUSIONS: On the basis of the results of this study, mindfulness meditation appears to be feasible and well tolerated in patients on hemodialysis with anxiety and depression symptoms. The study did not reveal significant effects of the interventions on depression and anxiety scores. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_10_12_CJASNPodcast_17_12_.mp3.
Authors: Patricia L Gerbarg; Vinita E Jacob; Laurie Stevens; Brian P Bosworth; Fatiha Chabouni; Ersilia M DeFilippis; Ryan Warren; Myra Trivellas; Priyanka V Patel; Colleen D Webb; Michael D Harbus; Paul J Christos; Richard P Brown; Ellen J Scherl Journal: Inflamm Bowel Dis Date: 2015-12 Impact factor: 5.325
Authors: Cynthia R Gross; Mary Jo Kreitzer; William Thomas; Maryanne Reilly-Spong; Michel Cramer-Bornemann; John A Nyman; Patricia Frazier; Hassan N Ibrahim Journal: Altern Ther Health Med Date: 2010 Sep-Oct Impact factor: 1.305
Authors: Gary Rodin; Jean A Mackay; Camilla Zimmermann; Carole Mayer; Doris Howell; Mark Katz; Jonathan Sussman; Melissa Brouwers Journal: Support Care Cancer Date: 2009-03-04 Impact factor: 3.603
Authors: Braden Kuo; Manoj Bhasin; Jolene Jacquart; Matthew A Scult; Lauren Slipp; Eric Isaac Kagan Riklin; Veronique Lepoutre; Nicole Comosa; Beth-Ann Norton; Allison Dassatti; Jessica Rosenblum; Andrea H Thurler; Brian C Surjanhata; Nicole N Hasheminejad; Leslee Kagan; Ellen Slawsby; Sowmya R Rao; Eric A Macklin; Gregory L Fricchione; Herbert Benson; Towia A Libermann; Joshua Korzenik; John W Denninger Journal: PLoS One Date: 2015-04-30 Impact factor: 3.240
Authors: Loan T Dang; Thuc C Luong; Dung H Nguyen; Trung A Hoang; Hoai T Nguyen; Hoang C Nguyen; Thai H Duong; Tu T Tran; Linh V Pham; Tuan V Ngo; Hoi T Nguyen; Nga T Trieu; Thinh V Do; Manh V Trinh; Tung H Ha; Dung T Phan; Binh N Do; Shwu-Huey Yang; Tsae-Jyy Wang; Tuyen Van Duong Journal: Nutrients Date: 2022-06-07 Impact factor: 6.706
Authors: Patrizia Natale; Suetonia C Palmer; Marinella Ruospo; Valeria M Saglimbene; Kannaiyan S Rabindranath; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2019-12-02
Authors: Bruno Nunes Razzera; Angélica Nickel Adamoli; Maitê Freitas Ranheiri; Margareth da Silva Oliveira; Ana Maria Pandolfo Feoli Journal: J Bras Nefrol Date: 2022 Jan-Mar
Authors: Carlos J Delgado-Domínguez; Sergio Sanz-Gómez; Ana López-Herradón; Beatriz Díaz Espejo; Olaya Lamas González; Macarena de Los Santos Roig; Isabel Berdud Godoy; Abraham Rincón Bello; Rosa Ramos Sánchez Journal: Int J Environ Res Public Health Date: 2021-03-29 Impact factor: 3.390